Aisling Capital Management LP
NEW YORK, NY
$472m in 14 US stocks at the end of 30 June 2026. The top 10 are 99.0% of the money. It changed about 7.6% of the portfolio this quarter.
Value
$472m
Stocks
14
Top 10 share
99.0%
Turnover
7.6%
What changed this quarter
New
Bought for the first time this quarter.
- vTv TherapeuticsVTVT0.4% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- BridgeBio PharmaBBIO72.5% of the fund-10%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Eupraxia PharmaceuticalsEPRX
- Share
- 0.5%
- Value
- $2m
- Shares
- 325,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| BridgeBio PharmaBBIO | 72.5% | $342m | 4,589,611 | -10% |
| Monte Rosa TherapeuticsGLUE | 8.0% | $38m | 1,555,664 | Held |
| Syndax PharmaceuticalsSNDX | 6.1% | $29m | 1,316,806 | Held |
| COMPASS PathwaysCMPS | 4.3% | $20m | 1,432,336 | Held |
| Bicara TherapeuticsBCAX | 3.6% | $17m | 568,919 | Held |
| BridgeBio Oncology TherapeuticsBBOT | 1.6% | $8m | 1,018,018 | Held |
| Scholar Rock HoldingSRRK | 0.9% | $4m | 77,031 | Held |
| UroGen PharmaURGN | 0.8% | $4m | 108,000 | Held |
| Biomea FusionBMEA | 0.6% | $3m | 2,048,757 | Held |
| Aclaris TherapeuticsACRS | 0.5% | $2m | 434,455 | Held |
| Eupraxia PharmaceuticalsEPRX | 0.5% | $2m | 325,000 | Held |
| vTv TherapeuticsVTVT | 0.4% | $2m | 50,000 | New |
| Marker TherapeuticsMRKR | 0.1% | $478,293 | 325,370 | Held |
| OnKure TherapeuticsOKUR | <0.1% | $404,048 | 88,607 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 31.1% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.